Gómez Tejeda Zañudo, Jorge http://orcid.org/0000-0002-1092-0068
Barroso-Sousa, Romualdo
Jain, Esha
Jin, Qingchun http://orcid.org/0000-0001-6388-5123
Li, Tianyu
Buendia-Buendia, Jorge E.
Pereslete, Alyssa http://orcid.org/0000-0001-7995-7507
Abravanel, Daniel L. http://orcid.org/0000-0002-0129-1618
Ferreira, Arlindo R.
Wrabel, Eileen
Helvie, Karla
Hughes, Melissa E.
Partridge, Ann H. http://orcid.org/0000-0002-4722-4824
Overmoyer, Beth http://orcid.org/0000-0003-4438-7000
Lin, Nancy U.
Tayob, Nabihah http://orcid.org/0000-0001-6088-167X
Tolaney, Sara M. http://orcid.org/0000-0002-5940-8671
Wagle, Nikhil http://orcid.org/0000-0003-3332-9438
Article History
Received: 9 October 2022
Accepted: 2 February 2024
First Online: 19 March 2024
Competing interests
: J.G. owns stocks in the biotechnology exchange-traded funds CNCR, IDNA, IBB, and XBI, and owned stocks in Adaptive Biotechnologies, 2seventy bio, and bluebird bio. R.B.-S. has received consulting fees from AstraZeneca, Eli Lilly, Libbs, Merck, Roche, and Zodiac; non-CME fees from Bard Access, BMS, Eli Lilly, Libbs, Merck, Novartis, Pfizer, and Roche; has carried out contracted research for Roche; and has received travel, accommodation and expenses from Eli Lilly, Roche, Daichi Sankyo, and Merck. E.J. is a current employee of Repare Therapeutics. J.E.B.-B. is a current employee of Cellarity. A.R.F. has received honoraria from Bayer, Daiichi Sankyo, Novartis, and Roche; and has received travel grants from Roche. N.U.L. has received consulting fees from Puma, Seattle Genetics, Daichii-Sankyo, AstraZeneca, Denali Therapeutics, Prelude Therapeutics, Olema Pharmaceuticals, Aleta BioPharma, Affinia Therapeutics, Voyager Therapeutics, Janssen, and Blueprint Medicines; has received institutional research support from Genentech, Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, and AstraZeneca; and has stocks and other ownership interests in Artera Inc. (<$50k and <5% as it relates to consulting activities—options are not currently valued or in-hand); and royalties from UptoDate (book). N.W. is a current employee of Genentech; has been a consultant/advisor for Eli Lilly; has been in the scientific advisory board for Relay Therapeutics and Flare Therapeutics; has received grant support from AstraZeneca and Puma Biotechnologies. S.M.T. reports consulting or advisory roles for Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, CytomX Therapeutics, Daiichi Sankyo, Gilead, Ellipses Pharma, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Myovant, Zetagen, Umoja Biopharma, Artios Pharma, Menarini/Stemline, Aadi Biopharma, Bayer, and Incyte Corp; and research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Gilead, Seattle Genetics, and OncoPep. The remaining authors declare no competing interests.